Endovascular treatment of indirect carotid-cavernous fistulas

As fístulas arteriovenosas da região do seio cavernoso constituem as fístulas carotidocavernosas que podem ser diretas ou indiretas. As indiretas são raras, a sua sintomatologia é variada e o tratamento é controverso. Este estudo compreendeu a análise prospectiva de 44 pacientes portadores de fístulas carotidocavernosas indiretas (FCCI) no período de 01 de janeiro de 1994 e 31 de janeiro de 2004, 42 com etiologia espontânea e dois pacientes com etiologia traumática, sendo estes analisados separadamente. Doze (12) pacientes foram submetidos à conduta expectante e orientados a realizar manobras de compressão carótido-jugular. O tratamento endovascular foi realizado por via arterial, venosa ou combinação dos dois, num total de 30 pacientes. Considerando o grupo inteiro, ocorreu trombose espontânea em aproximadamente 24% dos pacientes. Os sintomas e o aspecto angiográfico após o tratamento evoluíram com melhora ou cura em 100% dos casos, com oclusão completa das FCCI em 63,3%, a grande maioria destes submetidos a apenas um procedimento. Além dos acessos venosos tradicionais aos seios cavernosos, vias de acesso alternativas através da veia oftálmica superior foram realizadas por punção percutânea de veia facial, veia supratroclear ou veia frontal. O material embolizante mais utilizado foi o adesivo tissular líquido, \"cola\", isoladamente ou em conjunto com outros materiais. Houve complicações transitórias em 13,3% dos pacientes tratados e nenhuma complicação permanente foi observada, o que demonstrou a baixa morbidade deste procedimentoThe arteriovenous fistulas of the cavernous sinus (CS) region constitute the carotid-cavernous fistula, which can be direct or indirect. The indirect type is quite rare, its clinical features is very inespecific and its treatment modalities controversial. Forty-four patients with indirect carotid-cavernous fistulas (ICCF) were studied in a prospective manner between January 1994 to January 2004, 42 with spontaneous etiology and 2 with traumatic etiology, being these analyzed separately. Twelve (12) patients were submitted to a expectant management and instructed to perform carotid-jugular compression. Endovascular treatment was accomplished by arterial approach, vein approach or combination of both, in a total of 30 patients. Considering the entire group, spontaneous thrombosis was observed in approximately 24%. Symptoms and the angiographic features after endovascular treatment improved or disappeared in 100% of the cases, with total obliteration in 63.3%, most of them submitted to just one procedure. Despite the traditional venous routes to the CS, alternative accesses through the superior ophthalmic vein (SOV) were accomplished by percutaneous puncture of the facial, supratrochlear or frontal vein. Liquid adhesive (glue) was the most often embolic material used isolated or with other materials. No permanent complication was observed and only 13,3% of the patients treated cursed with transitory complications, what demonstrated the low morbidity of this procedur

Endovascular treatment of indirect carotid-cavernous fistulas

As fístulas arteriovenosas da região do seio cavernoso constituem as fístulas carotidocavernosas que podem ser diretas ou indiretas. As indiretas são raras, a sua sintomatologia é variada e o tratamento é controverso. Este estudo compreendeu a análise prospectiva de 44 pacientes portadores de fístulas carotidocavernosas indiretas (FCCI) no período de 01 de janeiro de 1994 e 31 de janeiro de 2004, 42 com etiologia espontânea e dois pacientes com etiologia traumática, sendo estes analisados separadamente. Doze (12) pacientes foram submetidos à conduta expectante e orientados a realizar manobras de compressão carótido-jugular. O tratamento endovascular foi realizado por via arterial, venosa ou combinação dos dois, num total de 30 pacientes. Considerando o grupo inteiro, ocorreu trombose espontânea em aproximadamente 24% dos pacientes. Os sintomas e o aspecto angiográfico após o tratamento evoluíram com melhora ou cura em 100% dos casos, com oclusão completa das FCCI em 63,3%, a grande maioria destes submetidos a apenas um procedimento. Além dos acessos venosos tradicionais aos seios cavernosos, vias de acesso alternativas através da veia oftálmica superior foram realizadas por punção percutânea de veia facial, veia supratroclear ou veia frontal. O material embolizante mais utilizado foi o adesivo tissular líquido, \"cola\", isoladamente ou em conjunto com outros materiais. Houve complicações transitórias em 13,3% dos pacientes tratados e nenhuma complicação permanente foi observada, o que demonstrou a baixa morbidade deste procedimentoThe arteriovenous fistulas of the cavernous sinus (CS) region constitute the carotid-cavernous fistula, which can be direct or indirect. The indirect type is quite rare, its clinical features is very inespecific and its treatment modalities controversial. Forty-four patients with indirect carotid-cavernous fistulas (ICCF) were studied in a prospective manner between January 1994 to January 2004, 42 with spontaneous etiology and 2 with traumatic etiology, being these analyzed separately. Twelve (12) patients were submitted to a expectant management and instructed to perform carotid-jugular compression. Endovascular treatment was accomplished by arterial approach, vein approach or combination of both, in a total of 30 patients. Considering the entire group, spontaneous thrombosis was observed in approximately 24%. Symptoms and the angiographic features after endovascular treatment improved or disappeared in 100% of the cases, with total obliteration in 63.3%, most of them submitted to just one procedure. Despite the traditional venous routes to the CS, alternative accesses through the superior ophthalmic vein (SOV) were accomplished by percutaneous puncture of the facial, supratrochlear or frontal vein. Liquid adhesive (glue) was the most often embolic material used isolated or with other materials. No permanent complication was observed and only 13,3% of the patients treated cursed with transitory complications, what demonstrated the low morbidity of this procedur

European Journal of Gastroenterology and Hepatology

Texto completo: acesso restrito. p.33-42Aim: This randomized controlled study evaluated the effect of autologous infusion of bone marrow cells (BMC) in patients with hepatic cirrhosis. Methods: Thirty patients on the liver transplant waiting list were randomly assigned to receive BMC therapy or no treatment. They were followed up for 1 year. The study was nonblinded. Autologous mononuclear-enriched BMC were infused into the hepatic artery; liver function scores/tests were chosen as endpoints to assess efficacy. Statistical analysis calculated mean relative changes (RC) from baseline and fitted a random-effects model. Results: Mean age, baseline model for end-stage liver disease, and Child–Pugh score were similar in both groups. Child–Pugh score improved in the first 90 days in the cell therapy group compared with controls (P = 0.017, BMC group RC = -8%, controls RC = +5%). The model for end-stage liver disease score remained stable in the treated patients (RC -2 to +6%), whereas it increased during follow-up in the control group (RC +6 to +18%). Albumin levels improved in the treatment arm, whereas they remained stable among controls in the first 90 days (P = 0.034; BMC group RC = +16%, control group RC = +2%). Bilirubin levels increased among controls, whereas they decreased in the therapy arm during the first 60 days; INR RC differences between groups reached up to 10%. The changes observed did not persist beyond 90 days. Conclusion: Transplantation of autologous BMC into the hepatic artery improved liver function in patients with advanced cirrhosis in the first 90 days. However, larger studies are necessary to define the role of BMC therapy in cirrhotic patients. Repeated autologous BMC infusions or combination therapy with granulocyte-colony-stimulating factor might improve or sustain the treatment response

World Journal of Gastroenterology

p. 1067-1073Aim: To evaluate the safety and feasibility of bone marrow cell (BMC) transplantation in patients with chronic liver disease on the waiting list for liver transplantation. Methods: Ten patients (eight males) with chronic liver disease were enrolled to receive infusion of autologous bone marrow-derived cells. Seven patients were classified as Child-Pugh B and three as Child-Pugh C. Baseline assessment included complete clinical and laboratory evaluation and abdominal MRI. Approximately 50 mL of bone marrow aspirate was prepared by centrifugation in a ficoll-hypaque gradient. At least of 100 millions of mononuclear-enriched BMCs were infused into the hepatic artery using the routine technique for arterial chemoembolization for liver tumors. Patients were followed up for adverse events up to 4 mo. Results: The median age of the patients was 52 years (range 24-70 years). All patients were discharged 48 h after BMC infusion. Two patients complained of mild pain at the bone marrow needle puncture site. No other complications or specific side effects related to the procedure were observed. Bilirubin levels were lower at 1 (2.19 ± 0.9) and 4 mo (2.10 ± 1.0) after cell transplantation that baseline levels (2.78 ± 1.2). Albumin levels 4 mo after BMC infusion (3.73 ± 0.5) were higher than baseline levels (3.47 ± 0.5). International normalized ratio (INR) decreased from 1.48 (SD = 0.23) to 1.43 (SD = 0.23) one month after cell transplantation. Conclusion: BMC infusion into hepatic artery of patients with advanced chronic liver disease is safe and feasible. In addition, a decrease in mean serum bilirubin and INR levels and an increase in albumin levels are observed. Our data warrant further studies in order to evaluate the effect of BMC transplantation in patients with advanced chronic liver disease. © 2007 The WJG Press. All rights reserved

Infusion of autologous bone marrow mononuclear cells through hepatic artery results in a short-term improvement of liver function in patients with chronic liver disease: a pilot randomized controlled study.

Submitted by Ana Maria Fiscina Sampaio ([email protected]) on 2014-11-27T19:22:21Z No. of bitstreams: 1 Lyra AC Infusion of....pdf: 209231 bytes, checksum: e2e73897c822b277bd8642ef46389981 (MD5)Approved for entry into archive by Ana Maria Fiscina Sampaio ([email protected]) on 2014-11-27T19:22:30Z (GMT) No. of bitstreams: 1 Lyra AC Infusion of....pdf: 209231 bytes, checksum: e2e73897c822b277bd8642ef46389981 (MD5)Made available in DSpace on 2014-11-27T19:40:51Z (GMT). No. of bitstreams: 1 Lyra AC Infusion of....pdf: 209231 bytes, checksum: e2e73897c822b277bd8642ef46389981 (MD5) Previous issue date: 2010Hospital Sao Rafael. Salvador, BA, Brasil / Hospital Universitário Professor Edgard Santos. Federal Univeristy of Bahia. Medicine-Gastro-Hepatology Service. Salvador, BA, BrasilHospital São Rafael. Regenerative Medicine. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, BrasilHospital Sao Rafael. Medicine. Hematology. Salvador, BA, BrasilHospital Sao Rafael. Salvador, BA, BrasilFundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, BrasilFundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, BrasilHospital São Rafael. Radiology. Salvador, BA, BrasilHospital São Rafael. Regenerative Medicine. Salvador, BA, BrasilBGStats Consulting. Graz, AustriaHospital São Rafael. Regenerative Medicine. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, BrasilHospital Sao Rafael. Salvador, BA, BrasilAIM: This randomized controlled study evaluated the effect of autologous infusion of bone marrow cells (BMC) in patients with hepatic cirrhosis. METHODS: Thirty patients on the liver transplant waiting list were randomly assigned to receive BMC therapy or no treatment. They were followed up for 1 year. The study was nonblinded. Autologous mononuclear-enriched BMC were infused into the hepatic artery; liver function scores/tests were chosen as endpoints to assess efficacy. Statistical analysis calculated mean relative changes (RC) from baseline and fitted a random-effects model. RESULTS: Mean age, baseline model for end-stage liver disease, and Child-Pugh score were similar in both groups. Child-Pugh score improved in the first 90 days in the cell therapy group compared with controls (P = 0.017, BMC group RC = -8%, controls RC = +5%). The model for end-stage liver disease score remained stable in the treated patients (RC -2 to +6%), whereas it increased during follow-up in the control group (RC +6 to +18%). Albumin levels improved in the treatment arm, whereas they remained stable among controls in the first 90 days (P = 0.034; BMC group RC = +16%, control group RC = +2%). Bilirubin levels increased among controls, whereas they decreased in the therapy arm during the first 60 days; INR RC differences between groups reached up to 10%. The changes observed did not persist beyond 90 days. CONCLUSION: Transplantation of autologous BMC into the hepatic artery improved liver function in patients with advanced cirrhosis in the first 90 days. However, larger studies are necessary to define the role of BMC therapy in cirrhotic patients. Repeated autologous BMC infusions or combination therapy with granulocyte-colony-stimulating factor might improve or sustain the treatment response